Hereditary Angioedema Therapeutic Market

The global hereditary angioedema therapeutic market size was valued at USD 2.2 billion in 2018 and is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing number of cases for hereditary angioedema.
 

Get Free Sample Report

Hereditary angioedema is a genetic disorder characterized from multiple recurring episodes of swelling known as angioedema. These swells happen in certain areas of the body such as the limbs, intestinal tract, airway, and face. Normally stress to minor trauma can trigger an attack, but swelling of the limbs can take place without known triggers. The swelling in the airway is especially dangerous considering it can restrict the host’s breathing leading to life-threatening obstruction. Mutation in genes can cause hereditary angioedema which can vary upon individuals. People facing malnutrition or people with limited immunities are more susceptible to this disease over others. According to the World Health Organization or the WHO and the National Organization for Rare Disorders or the NORD census report, about one in every nine people in any environment or condition can be affected by hereditary angioedema.

The COVID-19 pandemic has reduced the growth of the global hereditary angioedema therapeutic market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. Basically, a patient of hereditary angioedema was more susceptible to the COVID-19 virus than that of a healthy person. This steered to hospitals, clinics, and healthcare laboratories to focus more on hereditary angioedema therapies for the prevention and treatment of diseases and this led to its market growth in the later stages of this pandemic.

Market Trends, Drivers, Restraints, and Opportunities

• Increase in occurrences of hereditary angioedema along with the different innovative methods to treat this disorder is the primary reason for the projection of boosting the global hereditary angioedema therapeutic market growth during the forecast period, 2021-2028.
• There has been a rapid growth in the investment & funding towards the research & development activities towards hereditary angioedema therapeutic from the biopharmaceutical companies, which propels the market expansion in the coming years.
• High prices for the development of hereditary angioedema therapeutic equipment and high cost of services from the company’s perspective is anticipated to hinder the global hereditary angioedema therapeutic market growth. This becomes extremely difficult to function in developing countries such as India, South Africa and Brazil where there is limited healthcare infrastructure.
• Hereditary angioedema has been misdiagnosed by even the most educated doctors and physicians as this disease appears in different forms for different patients. This uncertainty could hinder the market growth.
• R&D activities along with studies have shown that the reasoning behind the misdiagnosis of hereditary angioedema is that they shared the same symptoms of other disorders such as gastrointestinal and appendicitis. New methods and innovations including the gene therapy has helped doctors and physicians to not only identify hereditary angioedema but also treat this disease according to the patients DNA and gene structure.

Scope of the Report

The report on the global hereditary angioedema therapeutic market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Hereditary Angioedema Therapeutic Market Segment Insights

C1-esterase inhibitor segment is estimated to signify the largest market share
Based on drug classes, the global hereditary angioedema therapeutic market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and others. The C1-esterase inhibitor segment is expected to constitute the major share of the market in 2019 and is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The major reason attributed to the dominant share of this segment is the products used for this treatment which has both prophylactic & on-demand treatment for hereditary angioedema.
 

Get Free Sample Report

On-demand segment is projected to register a large market share
Based on treatment types, the global hereditary angioedema therapeutic market is bifurcated into prophylaxis and on-demand. The on-demand segment is expected to constitute the major share of the market in 2019 and is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The major reason for this segment growth is attributed to continuous usage of on-demand products for the management of acute & chronic hereditary angioedema attacks. This method is also been preferred in almost all parts of the world and this segment is observing a geographical expansion.         

Intravenous segment is anticipated to register a huge market share
Based on the routes of administration, the global hereditary angioedema therapeutic market is divided into intravenous, subcutaneous, and oral. The intravenous segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is that the existing therapies used for the treatment of hereditary angioedema have been mostly administered by intravenous methods.

Meanwhile the subcutaneous segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. Patients have started to find difficulties to frequent intravenous methods causing hardships in their immunity levels. Subcutaneous have found superior advantages be it in time, money, efficiency, or efficacy.

North America is anticipated to dominate the market
On the basis of regions, the global hereditary angioedema therapeutic market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute the largest share in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology. The demand of hereditary angioedema therapies is increasing rapidly in this region due to the presence of the major market players in the market, an advantage no other region has. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of hereditary angioedema therapies combined with their growing population.
 

Get Free Sample Report

Segments

Segments Covered in the Report
The global hereditary angioedema therapeutic market size has been segmented in terms of

Drug Classes

• C1-Esterase Inhibitor
• Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

Treatment Types

• Prophylaxis
• On-Demand

Routes of Administration

• Intravenous
• Subcutaneous
• Oral

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• BioCryst Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Pharming Group N.V
• CSL Limited
• Shire Plc
• Attune Pharmaceuticals Inc
• Adverum Biotechnologies Inc
• KalVista Pharmaceuticals Inc

Competitive Landscape

Major players competing in the global hereditary angioedema therapeutic market are BioCryst Pharmaceuticals Inc; Ionis Pharmaceuticals Inc; Pharming Group N.V; CSL Limited; Shire Plc; Attune Pharmaceuticals Inc; Adverum Biotechnologies Inc; and KalVista Pharmaceuticals Inc. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Pharming Group N.V has appointed Inceptua Medicines Access to be their new business & distribution partner for the hereditary angioedema global access program in September 2019. This deal was aimed to help patients across geographies where hereditary angioedema is not available commercially so that every patient has access through ethical mechanisms and regulatory compliant to the products Pharming Group N.V provide.